ClinicalTrials.gg
RecruitingNCT07096297DarbeLusUpdated Sep 14, 2026

Luspatercept + Darbepoetin in MDS

A Phase 2 interventional study of Luspatercept and Darbeopoetin in MDS (Myelodysplastic Syndrome), sponsored by Yale University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.

Read the detailed description

This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.

Each participant will be treated with luspatercept in combination with darbepoetin alfa every 21 days (three weeks). Both agents will be administered on day 1 of each 21-day (three weeks) cycle. Based on the individual participant's response to combination therapy of luspatercept and darbepoetin alfa, the doses of luspatercept and/or darbepoetin alfa can be either decreased or increased.

02

Conditions studied

  • MDS (Myelodysplastic Syndrome)

Keywords

  • SF3B1 wild type
  • RBC transfusion dependent
  • lower risk
  • non-mutated SF3B1
03

In context

Lead sponsor

Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and the willingness to sign a written document.
  2. Participant is 18 years or older at the time of signing informed consent.
  3. Participant has lower-risk myelodysplastic syndrome (MDS) defined as very low, low and intermediate risk by International Prognostic Scoring System-Revised (IPSS-R) criteria (3).
  4. Bone marrow within 90 days of screening demonstrated less than 5% blasts in the aspirate and/or core biopsy. If no bone marrow biopsy was done within 90 days of screening it is mandatory to repeat it at screening. Otherwise, bone marrow biopsy is optional at screening to obtain correlative study samples.
  5. Absence of SF3B1 mutation and del5q.
  6. Endogenous serum erythropoietin alfa (EPO) level \< 500 IU/L.
  7. Participant is transfusion dependent defined as ≥ 2 packed red blood cell (PRBC) units/8 weeks for a minimum of eight weeks immediately prior to screening. The maximum consecutive timeframe participants may be RBC transfusion-free within this 8-week time period is six weeks.

    a. Red blood cell transfusions administered when levels were > 9.0 g/dL and/or RBC transfusions administered for elective surgery, infections or bleeding events will not be counted in above.

  8. Participant has an (ECOG) performance status of 0-3 (Appendix 1. ECOG Performance Status Scale).
  9. Participant has adequate organ function defined as:

    1. Serum /serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x , unless considered due to organ involvement by the participant's myeloid (in that case a cut off ≤ 5 x ULN will be used).
    2. Serum direct \< 1.5 x ULN.
    3. > 30 mL/min based on the Cockroft-Gault (GFR) estimation.
  10. Participants must adhere to the following reproductive and requirements while on study treatment and for three months after the last dose of luspatercept and darbepoetin alfa:

    a. General Requirements: i. Participants must not be pregnant or breastfeeding. ii. Participants must not donate gametes (i.e., eggs or sperm) or freeze gametes for future use related to assisted reproduction.

    b. For participants of : i. Participant of childbearing potential is defined as an individual who is premenopausal and capable of becoming pregnant, including those using contraception, those who are single, or those with partners who have had a vasectomy.

ii. A negative highly sensitive pregnancy test must be obtained at screening, and a negative serum or urine pregnancy test must be obtained within 72 hours starting on treatment, and participants must agree to further pregnancy tests throughout the study as required per the site's institutional guidelines.

iii. Participants must agree to use two methods of contraception of which one must be highly effective for three months after the last dose of luspatercept and darbepoetin alfa.

c. For Partners of Participants: i. If the participant's partner is of childbearing potential, the partner must also practice a highly effective method of contraception while the participant is on study treatment and for three months after the last dose of luspatercept and darbepoetin alfa, unless the participant is vasectomized.

d. Highly effective methods of contraception include, but are not limited to: i. Combined hormonal contraception (estrogen and progestogen) that inhibits ovulation (oral, intravaginal, or transdermal).

ii. Progestogen-only hormonal contraception that inhibits ovulation (oral, injectable, or implantable).

iii. Non-hormonal (cooper) intrauterine device (IUD). iv. Intrauterine hormone-releasing system. v. Bilateral tubal occlusion. vi. Sexual abstinence (the reliability of abstinence must be evaluated concerning the duration of the clinical study and the participant's lifestyle).

vii. A vasectomized partner (provided the partner is the sole sexual partner of the study participant of childbearing potential and that the vasectomized partner has received medical confirmation of the surgical success).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with ESA, luspatercept, hypomethylating agents or lenalidomide/thalidomide/other immunomodulating drug (IMiDs).

    1. Exception 1: Participants can have received ≤ 2 doses of prior epoetin alfa or ≤ 1 dose darbepoetin alfa if ≥ 8 weeks from date of consent.
    2. Exception 2: Participants can have received ≤ 1 week of treatment with lenalidomide ≥ 8 weeks from the date of consent, at the sponsor-investigator's discretion.
    3. After signing consent, the participants are not allowed to receive any of these drugs: other RBC hematopoietic growth factors (e.g., Interleukin-3), granulocyte colony stimulating factors (i.e., G-CSF, GM-CSF), except in cases of neutropenic fever, cytotoxic, chemotherapeutic, targeted or agents/therapies, azacitidine, decitabine or other hypomethylating agents, lenalidomide, thalidomide and other immunomodulating drugs (IMiDs), hydroxyurea, androgens, unless to treat hypogonadism, oral retinoids (topical retinoids are permitted), arsenic trioxide, interferon and interleukins.
  2. Participants with history of seizures at any time.
  3. Participants with any of the following conditions within six months prior to screening:

    1. Stroke.
    2. Thrombosis/thromboembolism.
    3. Myocardial infarction.
    4. Uncontrolled angina.
    5. Acute decompensated cardiac failure or (NYHA) Class III-IV heart failure.
    6. Uncontrolled cardiac arrhythmia as determined by the investigator.
  4. Participant has immediate life-threatening, severe complications of their myeloid such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
  5. Participants with uncontrolled hypertension defined as systolic blood pressure (SBP) of ≥ 150 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment. Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), .
  6. Participant has active viral infection with (HIV), or active infection with virus (HBV) or active infection with virus (HCV). Participants with HIV that is controlled (not detectable viral load) with highly active antiretroviral therapy (HAART) are eligible to participate.
  7. Participant has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
  8. Participant who is pregnant or lactating.

    1. Pregnant participants are excluded from this study because luspatercept has shown in animal studies to be potentially associated with fetal harm.
    2. Because there is an unknown but potential risk for AE in nursing infants secondary to treatment, lactating participants are excluded from this study.
  9. Participant with prior history of malignancies, other than MDS, unless the participant has been free of the disease for ≥ 5 years. However, participants with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin.
    2. Carcinoma in situ of the cervix.
    3. Carcinoma in situ of the breast.
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, TNM clinical staging system).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Luspatercept + Darbepoetin

    Each participant will be treated with luspatercept every 21 days (three weeks) in combination with darbepoetin alfa every 21 days (three weeks). Both agents will be administered on day 1 of each 21-day cycle. Based on the individual participant's response to combination therapy of luspatercept and darbepoetin alfa, the doses of luspatercept and/or darbepoetin alfa can be either decreased or increased. The starting dose is luspatercept at 1.0 mg/kg (Dose Level 0) and darbepoetin alfa 300 µg (Dose Level 0).

    Drug: Luspatercept · Drug: Darbeopoetin

Interventions

  • Luspatercept will be administered every 3 weeks (21 days) at a starting dose of 1.0 mg/kg (Dose Level 0). Luspatercept will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Participants must have Hgb, blood pressure and weight assessed (changes of body weight of ≤ ± 5% do not require a dose adjustment) prior to each luspatercept dose administration. Subcutaneous injections will be given in the upper arm, thigh, and/or abdomen. Volume for subcutaneous injection will be per institutional standard/guidelines.

  • DrugDarbepoetin alfaStudies of Darbepoetin alfaDarbepoetin alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Darbepoetin alfa will be administered every 3 weeks (21 days), at a starting dose of 300 ug (Dose Level 0). Darbepoetin alfa will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Darbepoetin alfa will be administered as a subcutaneous injection by the site staff in the upper arm, thigh, and/or abdomen per institutional standard/guidelines.

06

What researchers measure

Primary outcomes

  1. Mean Rate of Red Blood Cell Transfusion Independence

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least any consecutive 84 days (≥ 12 consecutive weeks) during weeks 1-24 compared to baseline in non-mutated SF3B1, lower-risk myelodysplastic syndrome patients treated with Luspatercept plus Darbepoetin Alfa

    Time frame: 24 weeks

  2. Mean Rate of Hemoglobin Increase

    Mean rate of hemoglobin ≥ 1.5 g/dL during weeks 1-24 compared to baseline in non-mutated SF3B1, lower-risk myelodysplastic syndrome patients treated with Luspatercept plus Darbepoetin Alfa.

    Time frame: 24 weeks

Secondary outcomes

  1. Mean rate of Red Blood Cell Transfusion Independence for ≥8 Consecutive Weeks During Weeks 1-24

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks during weeks 1-24 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 24 weeks of the study.

    Time frame: 24 weeks

  2. Mean rate of Red Blood Cell Transfusion Independence for ≥8 Consecutive Weeks During Weeks 1-48

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks during weeks 1-48 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 48 weeks of the study.

    Time frame: 48 weeks

  3. Mean rate of Red Blood Cell Transfusion Independence for ≥12 Consecutive Weeks During Weeks 1-24

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 12 consecutive weeks during weeks 1-24 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 24 weeks of the study.

    Time frame: 24 weeks

  4. Mean rate of Red Blood Cell Transfusion Independence for ≥12 Consecutive Weeks During Weeks 1-48

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 12 consecutive weeks during weeks 1-48 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 48 weeks of the study.

    Time frame: 48 weeks

  5. Mean rate of Red Blood Cell Transfusion Independence for ≥24 Consecutive Weeks During Weeks 1-24

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 24 consecutive weeks during weeks 1-24 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 24 weeks of the study.

    Time frame: 24 weeks

  6. Mean rate of Red Blood Cell Transfusion Independence for ≥24 Consecutive Weeks During Weeks 1-48

    Mean rate of red blood cell transfusion independence (RBC-TI) for at least 24 consecutive weeks during weeks 1-48 compared to baseline. Assessed as the proportion of participants who achieve RBC-TI within the first 48 weeks of the study.

    Time frame: 48 weeks

  7. Duration of Red Blood Cell Transfusion Independence for ≥8 Weeks

    To determine the duration of red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks. This outcome measure will evaluate how long participants maintain RBC-TI for a minimum of 8 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  8. Duration of Red Blood Cell Transfusion Independence for ≥12 Weeks

    Duration of red blood cell transfusion independence (RBC-TI) for at least 12 consecutive weeks. Assessed as how long participants maintain RBC-TI for a minimum of 12 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  9. Duration of Red Blood Cell Transfusion Independence for ≥24 Weeks

    To determine the duration of red blood cell transfusion independence (RBC-TI) for at least 24 consecutive weeks. Assessed as how long participants maintain RBC-TI for a minimum of 24 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  10. Median Time to Red Blood Cell Transfusion Independence for ≥8 Consecutive Weeks

    Median time to achieve red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks. Assessed as the median duration of time it takes for participants to achieve RBC-TI for a minimum of 8 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  11. Median Time to Red Blood Cell Transfusion Independence for ≥12 Consecutive Weeks

    Median time to achieve red blood cell transfusion independence (RBC-TI) for at least 12 consecutive weeks. Assessed as the median duration of time it takes for participants to achieve RBC-TI for a minimum of 12 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  12. Median Time to Red Blood Cell Transfusion Independence for ≥24 Consecutive Weeks

    Median time to achieve red blood cell transfusion independence (RBC-TI) for at least 24 consecutive weeks. Assessed as the median duration of time it takes for participants to achieve RBC-TI for a minimum of 24 weeks during the study period.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  13. Mean rate of Hematological Improvement Based on MDS 2018 IWG Response Criteria

    Mean rate of hematological improvement (HI) in participants as defined by the Myelodysplastic Syndromes (MDS) 2018 International Working Group (IWG) response criteria.

    Time frame: Assessed throughout the entire study period, approximately 2.5 years

  14. Changes in Health-Related Quality of Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Health-related quality of life (HRQoL) will be assessed using the EORTC QLQ-C30. This outcome measure will evaluate participants' overall quality of life, functional status, and symptom burden at various time points throughout the study. Scoring Range: 0 to 100 for each scale. Functioning Scales: Higher scores = better functioning. Symptom Scales: Higher scores = worse symptoms. Global Health Status/QOL Scale: Higher scores = better overall QOL.

    Time frame: At baseline, every 21 days during the treatment period, during the 24 week response assessment (approximately 169 days after beginning study treatment), at the end of treatment visit and during the 42 day follow up visit

  15. Changes in Anemia Outcome Measures Using the Functional Assessment of Cancer Therapy - Anemia (FACT-An) Questionnaire

    Changes in anemia-related quality of life using the FACT-An questionnaire. This outcome measure will evaluate the impact of anemia on participants' well-being, including physical, social, and emotional functioning, at various time points throughout the study. Scoring Range: 0 to 188 total. Higher scores=better QOL.

    Time frame: At baseline, every 21 days during the treatment period, during the 24 week response assessment (approximately 169 days after beginning study treatment), at the end of treatment visit and during the 42 day follow up visit

  16. Changes in Quality of Life Using the Quality of Life in Myelodysplasia Scale (QUALMS-P) Questionnaire

    Changes in quality of life specific to myelodysplasia using the QUALMS-P questionnaire. This outcome measure will evaluate the effects of myelodysplasia on participants' day-to-day life and overall well-being at various time points throughout the study. Total score 0-100. Higher scores=better QOL.

    Time frame: At baseline, every 21 days during the treatment period, during the 24 week response assessment (approximately 169 days after beginning study treatment), at the end of treatment visit and during the 42 day follow up visit

07

Study locations

1 of 4 sites recruiting
  • Yale University
    New Haven, Connecticut 06510, United States
    Recruiting
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute: Comprehensive Cancer Center (
    Columbus, Ohio 43210, United States
    Not yet recruiting
  • Harold C. Simmons Comprehensive Cancer Center of UT Southwestern
    Dallas, Texas 75235, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Aug 2030, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2025
First posted
Jul 31, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2030
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07096297
Lead sponsor
Yale University
Responsible party
Maximilian Stahl (Assistant Professor, Yale University) — Principal investigator
First posted
Jul 31, 2025
Start date
Dec 16, 2025
Primary completion
Aug 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Sep 14, 2026

Study contacts

Ashley Yu
Contact
ashley.yu@yale.edu
626-252-8737
Stephanie Ladd
Contact
stephanie.ladd@yale.edu
954-895-0576
Maximilian Stahl, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luspatercept

Start the discussion